+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

UK Bronchitis Treatment Market 2020-2026

  • PDF Icon


  • March 2021
  • Region: United Kingdom
  • Orion Market Research Private Limited
  • ID: 5332102
UK Bronchitis Treatment Market Size, Share & Trends Analysis Report by Type (Drugs (Antibiotics, Anti-Inflammatory Drugs, Bronchodilators, and Others) and Oxygen Therapy) and Forecast 2020-2026.

UK bronchitis treatment market is projected to witness considerable growth during the forecast period. The major factors that are driving the bronchitis treatment market in UK includes change in the lifestyle, including the high adoption of smoking habits among the adults in UK. This is leading to the rise in the prevalence of respiratory diseases, including asthma and bronchitis, which in turn, is augmenting the growth of the bronchitis treatment market in the country. As per Asthma UK, about 5.4 million people have asthma related problems in the UK out of which 1.1 million are children. The UK experience about three mortalities each day due to asthma. With such rising prevalence of asthma, the chances for bronchitis is increasing across the country, leading to its rise in the treatment facilities. Moreover, the NHS is spending near to 1 billion a year for the treatment and care of people with asthma related diseases. Therefore, the demand for bronchitis treatment is further expected to rise in UK, backed by the rising industrial sector and expansion of global market players in UK.

UK bronchitis treatment market is classified on the basis of type of treatment, which includes drugs and oxygen therapy. The drugs segment is further segregated into antibiotics, anti-inflammatory drugs, bronchodilators, and others. Among these types of treatments, the drugs find its significant application in the bronchitis treatment across the globe. In addition, the bronchodilator is estimated to project a considerable CAGR during the forecast period. Bronchodilators are the first-line medication used to treatment of bronchitis, to clear the airway obstruction, which is considered as first-step in chronic bronchitis to ease breathing problems.

The UK bronchitis treatment market is influenced by product development and advancements conducted by the market players. The key players of the bronchitis treatment market include Abbott Laboratories, Bayer AG, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. These players are playing a significant role in the growth of the bronchitis treatment market by providing various products and adopting several strategies such as merger and acquisition, partnerships and collaboration, technological development, and others.

Research Methodology

The market study of the UK bronchitis treatment market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. The research analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. UK Bronchitis Treatment Market Research and Analysis by Type

The Report covers:
  • Comprehensive research methodology of the UK bronchitis treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the UK bronchitis treatment market.
  • Insights about market determinants which are stimulating the UK market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. UK Bronchitis Treatment Market by Type
5.1.1. Drugs Antibiotics Anti-inflammatory drugs Bronchodilators Others (Mucolytics)
5.1.2. Oxygen Therapy

6. Company Profiles
6.1. Abbott Laboratories
6.2. Aurobindo Pharma Ltd.
6.3. Bayer AG
6.4. Boehringer Ingelheim International GmbH
6.5. Cipla Ltd.
6.6. Dr Reddy's Laboratories Ltd.
6.7. GlaxoSmithKline PLC
6.8. Lupin Pharmaceuticals, Inc.
6.9. Merck & Co., Inc.
6.10. Novartis AG
6.11. Pfizer Inc.
6.12. Sanofi SA
6.13. Teva Pharmaceutical Industries Ltd.List of Tables
1. Uk Bronchitis Treatment Market Research and Analysis by Type, 2019-2026 ($ Million)

List of Figures
1. UK Bronchitis Treatment Market Share by Type, 2019 Vs 2026 (%)
2. UK Bronchitis Treatment Market Size, 2019-2026 ($ Million)

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Dr Reddy's Laboratories Ltd.
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • . Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.